Unicycive Therapeutics, Inc. current report, 02 August 2022

Vollständiges Dokument

Unicycive Therapeutics, Inc. Form 8-K Summary

Business context and reporting period

This Form 8-K reports a Nasdaq continued-listing deficiency notice received on August 2, 2022. The company’s common stock trades under the symbol UNCY on the Nasdaq Capital Market. The filing was signed on August 8, 2022.

Key financial metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial statement metrics.

Material change versus the prior comparable period

Nasdaq notified the company that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The notice did not immediately affect the stock’s listing or trading status.

Guidance, outlook, risks, and contingencies

  • The company has until January 30, 2023, to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
  • If it does not regain compliance, the company may qualify for a second 180-calendar-day compliance period, subject to Nasdaq requirements.
  • If the company does not qualify for, or fails to regain compliance during, the second period, Nasdaq may issue a delisting determination.
  • The company may appeal a delisting determination to a Nasdaq hearings panel and stated that it will monitor its closing bid price and consider available compliance measures.
  • Key risks include failure to regain compliance, failure to satisfy other Nasdaq continued-listing requirements, and Nasdaq’s potential denial of relief from delisting.

Important facts for investors to verify

  • Whether UNCY regained compliance by January 30, 2023, or during any subsequent compliance period.
  • Whether Nasdaq issued any delisting determination, granted relief, or imposed additional conditions.
  • Whether the company implemented any actions that could affect its share price or capital structure, such as a reverse stock split.
  • The company’s latest financial condition, cash runway, and other risks described in subsequent Forms 10-K, 10-Q, and 8-K.